| MH | malignant histiocytosis; malignant hyperpyrexia; malignant hypertension; malignant hyperthermia; mam... |
|---|---|
| MRH | melanocyte-stimulating hormone-releasing hormone; multicentric reticulohistiocytosis |
| MRIH | melanocyte[-stimulating hormone] release-inhibiting hormone |
| MSHRH | melanocyte-stimulating hormone-releasing hormone |
| TSH-RH | thyroid-stimulating hormone-releasing hormone |
| receptors, granulocyte-colony-stimulating factor | Receptors that bind and internalise granulocyte-colony-stimulating factor. Their mw is believed to be 150 kD. These receptors are found mainly on a subset of myelomonocytic cells. (12 Dec 1998) |
|---|---|
| receptors, granulocyte-macrophage colony-stimulating factor | Receptors that bind and internalise the granulocyte-macrophage stimulating factor. Their mw is believed to be 84 kD. The most mature myelomonocytic cells, specifically human neutrophils, macrophages, and eosinophils, express the highest number of affinity receptors for this growth factor. (12 Dec 1998) |
| receptors, macrophage colony-stimulating factor | Glycoproteins of mw 165 kD which are encoded by the c-fms proto-oncogene. The binding of csf-1 to its receptors activates an intrinsic tyrosine kinase activity resulting in autophosphorylation of the receptors on tyrosine, rapid receptor down-regulation, and phosphorylation of as yet unidentified physiologic substrates that initiate a mitogenic response. (12 Dec 1998) |
| granulocyte-colony-stimulating factor | <growth factor, haematology, oncology> A glycoprotein of 25 kD containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukaemic myeloid cell lines. A protein that stimulates the growth and maturation of granulocytes. It is used to promote the recovery of the white cells following chemotherapy. See: colony-stimulating factor. Acronym: G-CSF (12 Dec 1998) |
| granulocyte-macrophage colony-stimulating factor | <growth factor, haematology, oncology> An acidic glycoprotein of mw 23 kD with internal disulfide bonds. It is produced in response to a number of inflammatory mediators by mesenchymal cells present in the haemopoietic environment and at peripheral sites of inflammation. It stimulates the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from foetal liver progenitor cells. It also has some functional activities in mature granulocytes and macrophages. It is used to promote the recovery of the white blood cells following chemotherapy. Chemical name: Colony-stimulating factor 2 See: colony-stimulating factor. Acronym: GM-CSF (12 Dec 1998) |
| colony-stimulating factor | <cell biology> A glycoprotein growth factor that regulates the differentiation of particular cells. These substances act in either paracrine or autocrine fashion on marrow cells, appear to act synergistically and can exert actions on several lines of progenitor cells, and influence end cell function. These lymphokines induce the maturation and proliferation of white blood cells from the primitive cell types present in bone marrow such as the leucocyte, macrophage and monocyte lines. These substances can also be made by recombinant DNA technology for use clinically to speed bone marrow recovery typically following chemotherapy. Acronym: CSF (18 Jul 2002) |
| multi-colony-stimulating factor | <cytokine> Product of mitogen activated T-cells: colony-stimulating factor for bone marrow stem cells and mast cells. A multilineage cell growth factor secreted by lymphocytes, epithelial cells, and astrocytes which stimulates clonal proliferation and differentiation of various types of blood and tissue cells. It is considered one of the haematopoietic colony-stimulating factors. Synonym: multi-CSF Acronym: IL-3 (12 Dec 1998) |
| multipotential colony-stimulating factor | <cytokine> Product of mitogen activated T-cells: colony-stimulating factor for bone marrow stem cells and mast cells. A multilineage cell growth factor secreted by lymphocytes, epithelial cells, and astrocytes which stimulates clonal proliferation and differentiation of various types of blood and tissue cells. It is considered one of the haematopoietic colony-stimulating factors. Synonym: multi-CSF Acronym: IL-3 (12 Dec 1998) |
| natural killer cell stimulating factor | <cytokine> A 75 kD heterodimeric cytokine composed of disulfide-bonded 40 kD and 35 kD subunits that was originally identified by its ability to induce cytotoxic effector cells in synergy with less than optimal concentrations of interleukin-2. It is released by macrophages in response to infection and promotes the activation of cell-mediated immunity. Specifically, IL-12 triggers the maturation of Thl CD4 cells, specific cytotoxic T-lymphocyte responses and an increase in the activity of NK cells and consequently, it is the initiator of cell-mediated immunity. It enhances the lytic activity of NK cells, induces interferon production, stimulates the proliferation of activated T-cells and NK cells. Is secreted by human B lymphoblastoid cells (NC 37). May play a role in controlling immunoglobulin isotype selection as it also inhibits IgE synthesis (even in the presence of anti-IFN monoclonal antibody) and as a growth factor for activated CD4+ and CD8+ T-cells independently of interleukin-2, and for CD56+ NK cells but not resting peripheral blood mononuclear cells or resting or activated tonsillar B-cells. It is likely that interleukin 12 has a major role in protective immunity against viruses and is under study as an immunotherapy in HIV infection. Formerly referred to as cytotoxic lymphocyte maturation factor. Acronym: IL-12 (12 Dec 1998) |
| immunoglobulins, thyroid-stimulating | Autoantibodies that bind to the thyroid-stimulating hormone (tsh) receptor (receptors, thyrotropin) on thyroid epithelial cells. The autoantibodies mimic tsh causing an unregulated production of thyroid hormones characteristic of graves' disease. (12 Dec 1998) |
| insulin-stimulating peptide | <chemical> 71-amino acid containing peptide; corresponds to residues 115-143 and 144-184 of bovine serum albumin with the exception of a tyrosine insertion between residues 155 and 156; consists of two chains with mw 5000 and 3400 for each chain Synonym: h-isp, insulin-stimulating protein (05 Dec 1998) |
| islet-cell-stimulating antibodies | <immunology> Autoantibodies to a putative beta-cell receptor; stimulate the release of insulin both in rodents and man; may be analogous to the thyroid stimulating antibodies that cause grave's hyperthyroidism Synonym: icsta (05 Dec 1998) |
| thyroid stimulating antibody | <endocrinology, immunology> Long acting thyroid stimulator is an autoantibody found in many cases of primary thyrotoxicosis which causes hyperplasia of the thyroid by undetermined mechanisms. Human thyroid stimulating immunoglobulin is a different antibody found in all or nearly all cases of primary thyrotoxicosis and may act by binding to the thyrotropin (TSH) receptor site, causing increased synthesis of thyroglobulin. (18 Nov 1997) |
| thyroid stimulating immunoglobulin | <protein> A test that measures the amount of an antibody (thyroid stimulating antibody) which is directed against a receptor for TSH on the thyroid gland. This antibody acts like TSH and stimulates the thyroid to produce excessive amounts of thyroid hormone. The presence of this antibody generally indicates Grave's disease (hyperthyroidism). (27 Sep 1997) |
| thyroid-stimulating immunoglobulins | In Graves' disease, the antibodies to TSH receptors in the thyroid gland. These antibodies are produced by B-lymphocytes and stimulate the receptors, causing hyperthyroidism. Formerly known as LATS (long-acting thyroid stimulator). (05 Mar 2000) |